Residency · Residency · Infectiousdisease

Tick-Borne Illnesses

Overview

Epidemiology

Tick-borne diseases represent the most common vector-borne diseases in the United States, with approximately 60,000 cases reported annually. This figure substantially underestimates the true burden, as studies suggest underreporting by a factor of three to five. Lyme disease alone accounts for roughly 80 percent of all reported tick-borne illness in the United States. These infections exhibit strong geographic concentration, with the Northeast and Upper Midwest regions served by Ixodes scapularis, the Pacific Coast by Ixodes pacificus, and the Southeast by Amblyomma and Dermacentor species.

An increasingly recognized clinical phenomenon is co-infection, in which a single tick bite transmits multiple pathogens simultaneously. This is most relevant for Ixodes scapularis, which can carry Borrelia burgdorferi, Anaplasma phagocytophilum, and Babesia microti concurrently, and a single feeding event may transmit all three agents. The possibility of co-infection should be considered in any patient whose clinical presentation is atypical or more severe than expected for a single tick-borne pathogen.

Major Tick Vectors in the US

The four principal tick vectors in the United States each transmit a distinct array of pathogens, and knowledge of the vector-pathogen associations is essential for clinical reasoning. Ixodes scapularis, the black-legged or deer tick, is the most important vector in the United States, transmitting Borrelia burgdorferi (Lyme disease), Anaplasma phagocytophilum (anaplasmosis), Babesia microti (babesiosis), Borrelia miyamotoi (relapsing fever-like illness), Powassan virus, and Ehrlichia muris eauclairensis.

Amblyomma americanum, the Lone Star tick, is the predominant tick in the southeastern United States and transmits Ehrlichia chaffeensis and Ehrlichia ewingii (ehrlichiosis), Heartland virus, Bourbon virus, and the agent of Southern Tick-Associated Rash Illness. The Lone Star tick is also the vector responsible for inducing alpha-gal syndrome through sensitization to galactose-alpha-1,3-galactose.

Dermacentor variabilis, the American dog tick, transmits Rickettsia rickettsii (Rocky Mountain spotted fever) and Francisella tularensis (tularemia). Dermacentor andersoni, the Rocky Mountain wood tick, similarly transmits R. rickettsii and F. tularensis and is also the vector for Colorado tick fever virus.

Lyme Disease

Epidemiology

Lyme disease, caused by Borrelia burgdorferi sensu stricto in the United States and by B. afzelii and B. garinii in Europe, is by far the most common tick-borne disease in the northern hemisphere. Over 30,000 cases are reported annually in the United States, but the CDC's 2021 estimate places the actual number of diagnosed cases at approximately 476,000 per year, reflecting extensive underreporting. The disease demonstrates a strong geographic predilection for the Northeast corridor extending from Connecticut to Maine, the Upper Midwest states of Wisconsin and Minnesota, and the Pacific Coast in northern California and Oregon. Transmission occurs predominantly during May through September, corresponding to the peak activity period of nymphal ticks, which are the primary vectors due to their small size and the resulting difficulty of detection. A critical fact for clinical decision-making is that the minimum tick attachment time required for transmission of B. burgdorferi from nymphal I. scapularis is 36 to 48 hours.

Clinical Stages

Lyme disease progresses through three clinical stages if untreated. Early localized disease manifests three to thirty days after the tick bite as erythema migrans, the hallmark skin lesion. Erythema migrans is an expanding erythematous lesion measuring at least 5 centimeters in diameter. The classic "bull's-eye" pattern with central clearing is present in only approximately 20 percent of cases; the majority of lesions are uniformly erythematous. The lesion is characteristically painless, and approximately 70 to 80 percent of patients with Lyme disease develop erythema migrans.

Early disseminated disease develops weeks to months after the initial infection and reflects hematogenous spread of the spirochete. Manifestations include multiple erythema migrans lesions at sites distant from the original bite, facial nerve (Bell) palsy that is bilateral in approximately 25 percent of cases, lymphocytic meningitis, Lyme carditis with atrioventricular block ranging from first-degree to complete heart block that may require temporary pacing, and migratory arthralgias.

Late Lyme disease manifests months to years after initial infection and is dominated by Lyme arthritis, a large-joint monoarticular or oligoarticular arthritis with a predilection for the knee. Recurrent joint effusions are typical. Late neuroborreliosis, including encephalopathy and peripheral neuropathy, is rare in the United States and more commonly associated with European Borrelia species, particularly B. garinii.

Diagnosis

The diagnosis of early localized Lyme disease, specifically erythema migrans, is a clinical one. A patient presenting with a characteristic expanding erythematous lesion in an endemic area during tick season should be treated empirically without waiting for serologic confirmation. This is because serology is negative in the first two to four weeks of infection, before the antibody response has developed.

For later stages of Lyme disease, the standard two-tier serologic algorithm consists of a first-tier enzyme immunoassay or immunofluorescence assay screen, followed by Western blot confirmation if the screen is positive or equivocal. IgM Western blot requires two of three bands at 23, 39, and 41 kDa, while IgG Western blot requires five of ten specified bands. A modified two-tier testing approach, cleared by the FDA in 2019, replaces the Western blot with a second enzyme immunoassay using VlsE/C6 peptide. This approach offers faster turnaround, easier standardization, and higher sensitivity in early disease.

Synovial fluid PCR is useful for diagnosing Lyme arthritis, with sensitivity of 70 to 85 percent, though serology is invariably positive in patients with Lyme arthritis and provides an important confirmatory role. For neuroborreliosis, cerebrospinal fluid analysis reveals lymphocytic pleocytosis and elevated protein, and calculation of a CSF Borrelia antibody index demonstrating intrathecal antibody production supports the diagnosis. CSF PCR is less sensitive than serology for neuroborreliosis.

Treatment

Treatment of early localized and early disseminated Lyme disease, including erythema migrans, early neuroborreliosis without parenchymal brain involvement, and carditis without high-degree atrioventricular block, consists of doxycycline 100 milligrams orally twice daily for 10 to 14 days. Doxycycline is the first-line agent and offers the additional advantage of covering potential Anaplasma co-infection. Alternatives include amoxicillin 500 milligrams three times daily for 14 days, which is preferred in pregnancy and children under eight years of age, and cefuroxime axetil 500 milligrams twice daily for 14 days.

Lyme meningitis, encephalitis, high-degree atrioventricular block, and ocular involvement require intravenous therapy, typically ceftriaxone 2 grams daily for 14 to 28 days. European data suggest that oral doxycycline may be non-inferior to intravenous ceftriaxone for Lyme meningitis, though this approach is not universally accepted in the United States.

Lyme arthritis is treated with doxycycline 100 milligrams twice daily for 28 days as first-line therapy. If arthritis persists after the initial course, a second 28-day oral course or intravenous ceftriaxone 2 grams daily for 14 to 28 days is appropriate. Antibiotic-refractory Lyme arthritis, defined as persistent synovitis more than three months after completion of two appropriate antibiotic courses, is believed to represent an autoimmune and inflammatory process rather than active infection. Treatment shifts to disease-modifying antirheumatic drugs such as methotrexate or hydroxychloroquine, NSAIDs, and intra-articular corticosteroid injections.

Prophylaxis

Single-dose doxycycline prophylaxis, consisting of 200 milligrams administered within 72 hours of tick removal, is effective for preventing Lyme disease after high-risk tick exposure. Criteria for prophylaxis include identification of the tick as Ixodes scapularis, estimated attachment duration of at least 36 hours or evidence of engorgement, exposure in an endemic area, and the absence of contraindications to doxycycline. The OspA-based LYMErix vaccine was withdrawn in 2002, and VLA15, a multivalent OspA vaccine, is currently in phase 3 clinical trials.

<image>A comprehensive clinical staging diagram for Lyme disease. Create three horizontal panels representing the three stages. Panel 1 "Early Localized (3-30 days)": show a classic erythema migrans lesion (expanding red lesion with partial central clearing) on the thigh, with annotation "70-80% of patients; clinical diagnosis, treat without serology." Panel 2 "Early Disseminated (weeks-months)": show four clinical manifestations: multiple EM lesions (disseminated), bilateral facial nerve palsy illustration, cardiac conduction system with AV block rhythm strip, and CSF tube labeled "lymphocytic meningitis." Panel 3 "Late (months-years)": show a swollen knee joint (Lyme arthritis) with synovial fluid analysis results. Below all panels, show the two-tier serology algorithm and modified two-tier testing approach. Include treatment regimens for each stage. Use a clinical textbook illustration style with anatomic detail.</image>

Rocky Mountain Spotted Fever (RMSF)

Clinical Features

Rocky Mountain spotted fever, caused by Rickettsia rickettsii, is the most lethal tick-borne disease in the United States, carrying a mortality rate of 20 to 30 percent in untreated patients but less than 5 percent when appropriate antibiotic therapy is administered promptly. The incubation period ranges from 2 to 14 days following a tick bite. The classic clinical triad consists of fever, headache, and rash, though the rash is present in only approximately 50 percent of patients at the time of initial presentation and is absent in 10 to 15 percent of confirmed cases, making early clinical recognition challenging.

The rash of RMSF characteristically begins on days two through five of illness as blanching macules on the wrists and ankles, subsequently spreading centripetally toward the trunk. As the disease progresses, the rash becomes petechial and purpuric, reflecting endothelial damage and vasculitis. Involvement of the palms and soles is a classic but late finding, observed in 40 to 80 percent of cases. Laboratory abnormalities include thrombocytopenia, hyponatremia, elevated liver transaminases, and elevated lactate dehydrogenase.

Diagnosis

Rocky Mountain spotted fever is a clinical diagnosis that demands empiric treatment whenever it is suspected. The physician must never wait for confirmatory testing before initiating therapy, as delay is directly associated with increased mortality. Serologic diagnosis by immunofluorescence assay requires demonstration of a fourfold rise in IgG titer between acute and convalescent samples drawn two to four weeks apart. A single titer of 1:64 or greater is suggestive but not confirmatory. Critically, serology is negative in more than 85 percent of cases during the first week of illness, the period when treatment decisions must be made. Skin biopsy of a rash lesion with direct fluorescent antibody testing or immunohistochemistry provides the most specific rapid diagnostic test, with sensitivity of approximately 70 percent. PCR from blood or tissue is available but has limited sensitivity during early disease.

Treatment

The treatment of Rocky Mountain spotted fever is doxycycline 100 milligrams orally or intravenously twice daily for 7 to 14 days, with the minimum duration being continuation until the patient has been afebrile for at least three days. Doxycycline is the treatment of choice for patients of all ages, including children under eight years of age. Both the American Academy of Pediatrics and the CDC explicitly recommend doxycycline for children with suspected RMSF, as short courses do not cause the dental staining historically associated with tetracycline-class antibiotics. Chloramphenicol should not be used, as it is associated with inferior outcomes and carries the risk of aplastic anemia. Delay in treatment beyond day five of illness dramatically increases mortality.

Anaplasmosis (Human Granulocytic Anaplasmosis)

Anaplasmosis, caused by Anaplasma phagocytophilum and transmitted by Ixodes scapularis, shares the same geographic distribution as Lyme disease in the northeastern and upper midwestern United States. The clinical presentation consists of fever, headache, myalgia, and malaise. A critical distinguishing feature is that rash is rare, occurring in fewer than 10 percent of cases, which helps differentiate anaplasmosis from RMSF and ehrlichiosis. The classic laboratory triad of leukopenia, thrombocytopenia, and elevated liver transaminases is highly suggestive of the diagnosis.

Diagnosis can be established by identification of morulae (characteristic intracytoplasmic inclusions) within neutrophils on peripheral blood smear, though sensitivity is limited at 20 to 60 percent. PCR from blood provides the highest sensitivity at greater than 90 percent during the acute phase and is the diagnostic modality of choice. Serology demonstrating a fourfold rise in antibody titer between acute and convalescent specimens confirms the diagnosis retrospectively. Treatment consists of doxycycline 100 milligrams twice daily for 10 to 14 days, with clinical response typically observed within 24 to 48 hours.

Ehrlichiosis (Human Monocytic Ehrlichiosis)

Ehrlichiosis, caused by Ehrlichia chaffeensis and transmitted by the Lone Star tick (Amblyomma americanum), is found predominantly in the southeastern and south-central United States. The clinical presentation includes fever, headache, myalgia, and gastrointestinal symptoms. A maculopapular rash, which is notably not petechial, occurs in 30 to 40 percent of patients. Laboratory findings of leukopenia, thrombocytopenia, and elevated liver transaminases mirror those of anaplasmosis.

Ehrlichiosis tends to be more severe than anaplasmosis, with a higher rate of hospitalization and complications. Severe disease may produce a hemophagocytic lymphohistiocytosis-like picture with pancytopenia and hyperferritinemia. Meningoencephalitis can occur in severe cases. Diagnosis is accomplished through identification of morulae within monocytes on blood smear, PCR, or serology. Treatment with doxycycline follows the same dosing as anaplasmosis.

Babesiosis

Babesiosis, caused by the intraerythrocytic protozoan Babesia microti and transmitted by Ixodes scapularis, is concentrated in the northeastern United States, with particular endemicity on islands and coastal areas including Nantucket, Martha's Vineyard, Long Island, and the Connecticut coast. Babesiosis is also the most common transfusion-transmitted parasitic infection in the United States, as infected donors may have asymptomatic parasitemia.

The clinical hallmark of babesiosis is hemolytic anemia, with fever, fatigue, jaundice, dark urine, elevated lactate dehydrogenase, elevated indirect bilirubin, low haptoglobin, and reticulocytosis. Disease can be severe and life-threatening in asplenic patients, the elderly, and immunocompromised individuals.

Diagnosis relies on examination of Giemsa-stained blood smear, which reveals intraerythrocytic ring forms. The "Maltese cross" or tetrad formation, representing four merozoites arranged in a cruciform pattern within a single erythrocyte, is pathognomonic but rarely observed. PCR is the most sensitive diagnostic modality. Serology supports the diagnosis but is not sufficient alone.

Treatment is stratified by severity. Mild to moderate disease is treated with atovaquone 750 milligrams twice daily plus azithromycin (500 to 1,000 milligrams on day one, then 250 milligrams daily) for 7 to 10 days. Severe disease, defined by parasitemia exceeding 4 percent, significant hemolysis, or renal, hepatic, or pulmonary compromise, requires intravenous clindamycin 600 milligrams every six hours plus oral quinine 650 milligrams every six to eight hours for 7 to 10 days. Exchange transfusion should be considered when parasitemia exceeds 10 percent or when severe hemolysis and organ failure are present. In patients with co-infection with Lyme disease, both infections should be treated simultaneously.

<image>A differential diagnosis comparison table for the major tick-borne diseases in the US. Create a grid with columns for: Lyme Disease, RMSF, Anaplasmosis, Ehrlichiosis, and Babesiosis. Rows should include: causative organism, tick vector, geographic distribution (with small US map icons), incubation period, key clinical features, rash characteristics (with small illustrations), characteristic lab findings, diagnostic method of choice, and first-line treatment. Use color coding: green for Ixodes-transmitted, red for Dermacentor-transmitted, orange for Amblyomma-transmitted. Highlight distinguishing features: "Rash RARE" for anaplasmosis, "Hemolytic anemia" for babesiosis, "Petechial rash palms/soles" for RMSF, "Erythema migrans" for Lyme. Professional medical reference table format.</image>

Other Tick-Borne Diseases

Tick-Borne Relapsing Fever

Tick-borne relapsing fever is caused by Borrelia hermsii and transmitted by soft ticks of the genus Ornithodoros, which are found in rustic mountain cabins in the western United States. The hallmark clinical feature is relapsing episodes of high fever lasting three to five days, separated by afebrile intervals, reflecting antigenic variation by the spirochete. Diagnosis is established by identification of spirochetes on a blood smear obtained during a febrile episode. Treatment consists of doxycycline, and the clinician should be aware that a Jarisch-Herxheimer reaction is common upon initiation of therapy. Pretreatment with acetaminophen can help mitigate this reaction.

Tularemia

Tularemia is caused by Francisella tularensis and transmitted by Dermacentor and Amblyomma ticks, though it can also be acquired through contact with rabbits or rodents or through inhalation of aerosolized organisms. The ulceroglandular form, characterized by a skin ulcer at the inoculation site with regional lymphadenopathy, is the most common clinical presentation. The pneumonic form, which carries bioterrorism implications, presents as a severe community-acquired pneumonia. Treatment of severe tularemia requires streptomycin or gentamicin, while mild disease can be treated with doxycycline or ciprofloxacin.

Alpha-Gal Syndrome

Alpha-gal syndrome is a novel allergic condition induced by the bite of the Lone Star tick (Amblyomma americanum), which sensitizes the host to galactose-alpha-1,3-galactose, a carbohydrate found on mammalian cell surfaces. The resulting IgE-mediated allergic reaction to mammalian red meat, including beef, pork, and lamb, is distinctive for its delayed onset of three to six hours after ingestion, in contrast to the rapid onset typical of other food allergies. Diagnosis is established by measurement of specific IgE to alpha-gal. Alpha-gal syndrome is emerging as a significant food allergy, with over 100,000 cases estimated in the United States.

Key Clinical Pearls

• RMSF is a clinical diagnosis that requires empiric doxycycline -- waiting for serology to confirm can be fatal; serology is negative in >85% during the first week
• Doxycycline is safe in children of all ages for tick-borne diseases -- do not withhold due to age-related concerns about dental staining (short courses are safe)
• Co-infection (Lyme + babesiosis + anaplasmosis) is common with Ixodes ticks -- always consider testing for multiple pathogens
• Lyme serology is negative in early erythema migrans -- treat clinically; do NOT require positive serology to treat classic EM in an endemic area
• Babesiosis can be severe in asplenic and immunocompromised patients -- exchange transfusion may be lifesaving for parasitemia >10%
• The triad of leukopenia + thrombocytopenia + elevated transaminases should immediately suggest anaplasmosis or ehrlichiosis -- treat with doxycycline while awaiting confirmation
• Single-dose doxycycline prophylaxis (200mg) is effective for preventing Lyme disease after high-risk tick exposure -- must be given within 72 hours

References

1. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis (IDSA 2006). Clin Infect Dis. 2006;43(9):1089-1134.
2. Biggs HM, Behravesh CB, Bradley KK, et al. Diagnosis and management of tickborne rickettsial diseases (CDC 2016). MMWR Recomm Rep. 2016;65(2):1-44.
3. Krause PJ, Auwaerter PG, Bannuru RR, et al. Clinical practice guidelines by the IDSA, AAN, and ACR: 2020 guidelines for the prevention, diagnosis, and treatment of Lyme disease. Clin Infect Dis. 2021;72(1):e1-e48.
4. Vannier EG, Diuk-Wasser MA, Ben Mamoun C, Krause PJ. Babesiosis. Infect Dis Clin North Am. 2015;29(2):357-370.
5. Commins SP, James HR, Kelly LA, et al. The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-alpha-1,3-galactose. J Allergy Clin Immunol. 2011;127(5):1286-1293.

Read this lecture as Markdown